Oligonucleotide Synthesis Market Analysis 2018-2027: Molecular Assemblies, Twist Biosciences, Evonetix, DNA Script, Nuclera Nucleics, Camena Bioscience, Synthomics, Ansa Biotechnologies and Helixworks

The global oligonucleotide synthesis market accounted to US$ 1,584.16 Mn in 2018 and is expected to grow at a CAGR of 11.1% during the forecast period 2019 - 2027, to account to US$ 3,971.72 Mn by 2027.

Increasing applications of synthesized oligonucleotides, increasing investments for synthetic biology and technological advancements genome editing tools are the key driving factors for the growth of the market in the forecast period. However, the growth of the market is restrained by factors such as renewed regulations for biotechnology and lack of skilled professionals in life science industry.

Get sample PDF copy: http://bit.ly/2DQRJJn

Increasing Applications of Synthesized Oligonucleotides is driving the market for Oligonucleotide Synthesis over the forecast period.

The oligonucleotide synthesis market by product is segmented into synthesized oligonucleotides, reagents and equipment. In 2018, the synthesized oligonucleotides segment held a largest market share of 48.3% of the oligonucleotide synthesis market, by product. This segment is also expected to dominate the market in 2027 owing to its benefits offered in applications such as research, diagnostics and therapeutics. In addition to diagnostic and therapeutic purpose, oligonucleotides are also used for designing DNA microchips that are used as a powerful bio-analytical tool and novel material in the field of nanotechnology.

Some of the players operating in oligonucleotide synthesis market are, Molecular Assemblies, Twist Bioscience, Evonetix, Nuclera Nucleics Ltd., Camena Bio, DNA Script, Iridia, Inc., Helixworks, Ansa Biotechnologies, Inc., and Synthomics, Inc., among others.

The market players have been establishing partnerships as well as collaborations in the market, which enables them to hold a strong position in the market. For instance, in October, 2018, EVONETIX LTD pioneering an innovative approach to scalable and high-fidelity gene synthesis, and LioniX International, a leading global provider of customised microsystem solutions in scalable production volumes, collaborated to scale up production of prototype microelectromechanical systems (MEMs) for DNA synthesis.The developments performed by the companies are helping the market to grow in the coming years.

Buy this complete report @ http://bit.ly/2DRJAEN

Strategic Insights

Strategic acquisition and product launches were observed as the most adopted strategy in global oligonucleotide synthesis industry. Few of the recent product launch and acquisitions are listed below:

2018: Twist Bioscience has developed sample preparation products for customers performing next-generation sequencing experiments and analysis. The Twist Human Core Exome Kit includes all the tools needed for library construction, target capture and enrichment to prepare a sample for sequencing.

2018: Twist Bioscience Corporation expanded its North American operations with establishing a new office in San Diego area. The office supports sales and marketing and other corporate administrative functions and will be the headquarters for customer support for the company’s recently-launched solutions to enhance next-generation sequencing.

2018: EVONETIX LTD pioneering an innovative approach to scalable and high-fidelity gene synthesis, and LioniX International, a leading global provider of customised microsystem solutions in scalable production volumes, collaborated to scale up production of prototype microelectromechanical systems (MEMs) for DNA synthesis.

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com
Web: https://www.theinsightpartners.com/

This release was published on openPR.